media from genes to therapy molmed s.p.a. is a medical biotechnology company focused on research development and clinical validation of innovative therapies to treat cancer . important stuff news nov 7 2016 ordinary and extraordinary shareholders meeting last update oct 7 2016 oct 18 2016 oct 21 2016 esgct 2016 last update oct 3 2016 oct 5 2016 oct 7 2016 cell & gene meeting on the mesa last update sep 17 2016 read all products of excellence ngr htnf today status tk today status gmp solutions molmed gmp solutions provides tailor made services for your cell & gene therapy projects . read scientific stuff publications poster jun 1 2015 asco treatment free interval tfi after first line therapy as a prognostic and predictive factor in malignant pleural mesothelioma ... poster jun 1 2015 asco prognostic and predictive value of neutrophil to lymphocyte ratio nlr in previously treated patients oral presentation may 30 2015 asco phase 3 trial ngr015 with ngr htnf plus best investigator choice bic versus placebo plus bic in previously treated patients with advanced malignant pleural mesothelioma read all last presentation sep 11 2016 sep 13 2016 rodman & renshaw 18th annual global investment conference new york usa molmed company presentation september 2016 download 201620152014all presentations financial reports annual financial report english translation for convenience 2015 download half year financial report english translation for convenience at 06 30 2016 download interim financial report english translation for convenience at 03 31 2016 download interim financial report in italian at 09 30 2015 download 201620152014all financial reports press stuff press releases oct 6 2016 resolutions by the board of directors of molmed s.p.a. download sep 9 2016 data presented at ebmt symposium support zalmoxis innovative therapy potential in addressing life threatening condition download sep 1 2016 molmed future revenues will benefit from a review of the strategic agreement with glaxosmithkline download read all subscribe to press releases name email working at molmedmolmed is aware that highly qualified and skilled personnel are of key importance to the company oct 4 2016 project & partner manager sep 30 2016 transfer technologist apr 6 2016 gmp manufacturing technician read all partnering molmed s business strategy strongly relies on establishing strategic alliances in order to foster the development of its leading products read notice this is the only official website of molmed s.p.a. the company is therefore not liable for the dissemination of news information and or data which might appear on other sites blogs social networks or other web resources which may unlawfully use the name of the company as the holder of such contents . companybusiness model history management scientific advisory board careers clinical trialstk ngr htnf faq pipelinetk ngr htnf car cd44v6 tech . platformscell and gene therapy vascular targeting patents publications gmp solutionsdevelopment gmp manufacturing quality control quality assurance regulatory affairs facilities track record partneringpartners investorsstock market corporate governance shareholder information financial reports analyst coverage press releases investors events mediaevents news molmed s.p.a. via olgettina 58 20132 milano italy phone 39 0221277 .1 fax 39 02 21277.325 info molmed.com www.molmed.com share capital 19 841 682 .30 fully paid office of milan company registry number 1506630 tax identification number 11887610159 home company clinical trials pipeline technological platforms gmp solutions partnering investors media